期刊文献+

卡泊芬净治疗恶性血液病并发侵袭性真菌感染患者的疗效观察

Effect of caspofungin on patients with hematologic malignancies and invasive fungal infections
原文传递
导出
摘要 恶性血液病患者因接受大剂量化疗,应用免疫抑制剂及广谱强效抗生素,造成中性粒细胞严重减少,免疫功能明显下降,极易发生侵袭性真菌感染(IFI)。抗真菌治疗疗程长,而多数并发真菌感染者的基础疾病重,对药物耐受性差,老年患者更为突出。我院采用卡泊芬净治疗恶性血液病并发IFI患者41例,观察其疗效和安全性,报告如下。
出处 《临床血液学杂志》 CAS 2013年第4期490-491,共2页 Journal of Clinical Hematology
关键词 恶性血液病 侵袭性真菌感染 卡泊芬净 hematologic malignancies invasive fungal infections caspofungin
  • 相关文献

参考文献9

  • 1PAGAN() L, CAIRA M, VALENTINI C G, et al. Current therapeutic approaches to fungal in{ections in immunocompromised hematological patients[J]. Blood Rev,2010,24:51 61.
  • 2血液病/恶性肿瘤患者侵袭性真菌感染的诊断标准与治疗原则(第三次修订)[J].中华内科杂志,2010,49(5):451-454. 被引量:196
  • 3BORECKA S, PINJON E, SULLIVAN D J, et al. Cdr2p contributes to fluconazole resistance in Candida dubliniensis clinical isolates [J] Can J Microbiol, 2011,57:416-426.
  • 4SCHULER U,BAMMER S,AULITZKY W E,et al. Safety and efficacy of itraconazole compared to am- photericin B as empirical antifungal therapy for neu- tropenic fever in patients with haematological malig nancy[J]. Onkologie, 2007,30 : 185 - 191.
  • 5陈懿建,张立群,万通,李海亮,刘礼平,赖文鸿.两性霉素B脂质体治疗恶性血液病侵袭性真菌感染的临床观察[J].临床血液学杂志,2011,24(6):683-685. 被引量:7
  • 6王海燕,崔杰,黄祥,王玉兰.卡泊芬净治疗老年患者侵袭性真菌感染临床分析[J].中国药物应用与监测,2009,6(5):266-269. 被引量:3
  • 7JOSEPH J M,JAIN R,DANZIGER L H. Mieafungin: a new echinocandin antifungal[J]. Pharmacotherapy, 2007,27:53-67.
  • 8NAKAGAWA Y, LCHII Y, SAEKI Y, et al. Plasma con- centration of micafungin in patients with hematologic ma- lignancies[J] J Infect Chemother, 2007,13 : 39-45.
  • 9GLOCKNER A, STEINBACH A, VEHRESCHILD J J,et al. Treatment of invasive candidiasis with echino- candins[J]. Mycoses, 2009,52 : 476- 486.

二级参考文献24

  • 1徐晓峰,刘双,张艳艳,高伟,李京明.念珠菌菌血症22例临床分析[J].中华内科杂志,2005,44(3):215-216. 被引量:7
  • 2沈志祥,陈秋生.血液病合并侵袭性真菌感染的临床特点与治疗[J].中华医学杂志,2005,85(21):1447-1448. 被引量:41
  • 3侵袭性肺部真菌感染的诊断标准与治疗原则(草案)[J].中华内科杂志,2006,45(8):697-700. 被引量:867
  • 4血液病/恶性肿瘤患者侵袭性真菌感染的诊断标准与治疗原则(修订版)[J].中华内科杂志,2007,46(7):607-610. 被引量:250
  • 5Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infection in imrnunocompromised patiens with cancer and hematopoietic stem cell transplants: an international consensus[J]. Clin Infect Dis, 2002, 34(1): 7-14.
  • 6Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy[J]. Clin Infect Dis, 2004, 39(11): 1563-1571.
  • 7Glasmacher A, Cornely OA, Orlopp K, et al. Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients[J]. J Antimicrob Chemother, 2006, 57(1): 127-134.
  • 8Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis[J]. N Engl J Med, 2002, 347(25): 2020-2029.
  • 9CAILLOT D, THI_EBAUT A, HERBRECHT R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies[J].Cancer, 2007,110:2740 --2746.
  • 10MOEN M D, LYSENG-WILLIAMSON K A, SCOTT L J. Liposomal amphotericin B:a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections [J]. Drugs, 2009,69:361--392.

共引文献203

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部